Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data

Five Prime Therapeutics,Inc.
Posted on: 08 Nov 17

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that it will host a conference call and live audio webcast on Wednesday, November 8, 2017, at 8:00 a.m. (ET) to review data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo® (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor. An abstract of the data has been selected for a late-breaking oral presentation on Saturday, November 11, 2017, at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting in National Harbor, Maryland. The late-breaking abstracts were published today by SITC.

Five Prime originally intended to host the call and webcast on November 7, 2017, but an extended GlobeNewswire outage prevented a press release from being issued. In advance of the event tomorrow, Five Prime will file a Current Report on Form 8-K with the Securities and Exchange Commission that will include the slides to accompany the conference call presentation and discussion. Five Prime’s management will provide important additional details during the call.

The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 8687899.

The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit

View source version on

Business Wire

Last updated on: 08/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.